Skip to content

Single-cell precision diagnostics

Analyzing single cells offers unprecedented biological resolution. Scailyte develops cutting edge analytical pipelines to translate this data into clinical applications.
Supported by
MC logo
venture logo

Our pillars

High-quality biomedical data sets

in disease areas with unmet need for early and accurate diagnostics, generated through excellent project design and execution in partnership with top clinical researchers.

Targeted and sensitive algorithms

to extract clinically relevant insight, integrated into a proprietary data analytics platform through continuous development and application of most appropriate technology.

Industrialization and adoption

of our ultra-sensitive biomarkers, through an established and growing network of top clinicians and industry leaders in diagnostics and pharma.

On a mission to save millions of lives.

Single-cell data offers unprecedented biological resolution but is overly complex to analyze and interpret. Scailyte develops new data analytics approaches with the aim to extract clinically relevant insights and turn them into applications that will improve patient outcomes and save millions of lives.

We are applying ScaiVision, our proprietary biomarker discovery platform, to discover novel molecular signatures from single-cell data and develop the next generation of precision diagnostics.

From discovery to next generation clinical applications

Study Design

Defining hypothesis

Wet/Dry lab setup and experimental design

Data analysis workflow

Data Acquisition

Identification of suitable single-cell method(s)
Method optimization
Sample preparation and processing

Biomedical insights

Data processing, analysis and interpretation using our AI-based technology
Identification of biomarkers and cell-identity signatures

Diagnostic development

Data processing, analysis and interpretation using our AI-based technology
Identification of biomarkers and cell-identity signatures

Establishing a precision diagnostics portfolio

Single-cell data allows an unprecedented insight into health and disease, opening new avenues for diagnostics and therapeutics of complex diseases like cancer and immune disorders.
+ 6 new indications to be initiated in 2020/2021

Accelerating innovation through partnerships

Making groundbreaking discoveries and bringing innovations into clinical practice require collaborations and joint-ventures.

Scailyte provides a unique solution by our discovery platform using single cell technology and artificial intelligence to advance discoveries in life science faster. We are always looking for partners to accelerate this further to address the unmet needs for patients.

We are multi-disciplinary team with tech, science and business expertise.

Our investors

Recent News

Interview with Scailyte’s CEO Peter Nestorov

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO

Read more

Recent News

Interview with Scailyte Founder Prof. Dr. Manfred Claassen

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri

Read more

Recent News

Postdoc (Ph.D.) opportunity in Molecular Biology

This postdoctoral Research position in the laboratory of Endometriosis and Gynecological Oncology is

Read more

Recent News

Scailyte: simplifying difficult diagnoses

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare

Read more

Recent News

Scailyte among The Spinoff Prize finalists

Scailyte is among the ten selected young science-based university spinoff companies that showcase th

Read more

Recent News

Scailyte closes pre-series A financing round

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to furthe

Read more

Recent News

Scailyte and CHU Rennes partnership for identifying Covid-19 patients

Scailyte and CHU Rennes have made an initial discovery of a single-cell

Read more

Recent News

Scailyte announces its new advisory board

ScailyteTM is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to

Read more

Recent News

01 /04

Interview with Scailyte’s CEO Peter Nestorov

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO

Read more

Interview with Scailyte Founder Prof. Dr. Manfred Claassen

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri

Read more

Recent News

02 /04

Postdoc (Ph.D.) opportunity in Molecular Biology

This postdoctoral Research position in the laboratory of Endometriosis and Gynecological Oncology is

Read more

Scailyte: simplifying difficult diagnoses

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare

Read more

Recent News

03 /04

Scailyte among The Spinoff Prize finalists

Scailyte is among the ten selected young science-based university spinoff companies that showcase th

Read more

Scailyte closes pre-series A financing round

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to furthe

Read more

Recent News

04 /04

Scailyte and CHU Rennes partnership for identifying Covid-19 patients

Scailyte and CHU Rennes have made an initial discovery of a single-cell

Read more

Scailyte announces its new advisory board

ScailyteTM is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to

Read more

Recent News